Becton, Dickinson and CompanyNYSE: BDX

No material news in the last 48 hours.

No material news in the last 48 hours.

Becton Dickinson named Vitor Roque EVP and CFO effective May 7, 2026, after serving as interim CFO since December 2025. The company posted Q2 FY2026 revenue of $4.714B (up 5.2%) and adjusted EPS of $2.90, beating $2.78 consensus. BDX executed a $2.0B accelerated share repurchase, retired $2.1B of debt, and raised full-year adjusted EPS guidance to $12.52-$12.72. On May 5, BD announced a strategic partnership with Wellstar Health System. New EVP Peter Menziuso named president of BD Interventional on May 18. Barclays raised its price target to $204.

BD Q2 FY26 EPS Beatinvesting.comBD Appoints Vitor Roque CFOprnewswire.comBDX Q2 Results and FY2026 Outlookquiverquant.com

No material news in the last 48 hours.

On May 18, 2026, Becton Dickinson named Peter Menziuso EVP and president of BD Interventional, succeeding Rick Byrd who is retiring after nearly 25 years. The appointment follows BD's May 7 Q2 FY26 results in which the company beat with $2.90 adjusted EPS, raised full-year adjusted EPS guidance to $12.52-$12.72, executed a $2.0B ASR, and retired $2.1B of debt. Barclays raised its price target to $204 on the strong Q2 print. Bear case: the Interventional segment is undergoing leadership turnover at a time when device-segment growth must accelerate to meet raised guidance.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBecton Dickinson & (BDX) Stock News & Updatesstocktitan.net

No material news in the last 48 hours. BDX traded with a Buy consensus rating as of May 18 at around $143. Q2 FY2026 results on May 7 beat expectations with adjusted EPS of $2.90, and full-year guidance was raised to $12.52-$12.72.

Becton Dickinson Q2 2026 Earnings Transcript - Globe and Mailtheglobeandmail.comBDX jumps after Q2 results and raised FY2026 EPS outlook - QuiverQuantquiverquant.comBDX Stock Forecast - Public.compublic.com

Becton, Dickinson reported fiscal Q2 revenue of $4.71B and adjusted EPS of $2.90, beating estimates, and raised FY adjusted EPS guidance to $12.52-$12.72 despite divestiture headwinds and a net loss. Vitor Roque, who has served as interim CFO since December 2025, was named permanent EVP and CFO effective May 7. The company received multi-category supply chain resilience awards, launched the HemoSphere Stream Module for continuous noninvasive blood pressure monitoring, highlighted new PureWick clinical data, and advanced its Liverty TIPS Stent Graft program in portal hypertension. Barclays raised PT to $204 from $202 with Overweight. Analyst consensus is Buy with $184.69 average 12-month PT (~28% upside). Risk: ongoing Alaris and divestiture pressures.

Becton Dickinson price target raised to $204 from $202 at Barclaystipranks.comHow Investors May Respond To Becton Dickinson (BDX) Expanding Clinically Differentiated Devicessimplywall.stBDX Maintained by Barclays -- Price Target Raised to $204gurufocus.com

BD reported Q2 fiscal 2026 results on May 7 with revenue of $4.714B, up 5.2% reported (2.6% currency-neutral), and adjusted diluted EPS of $2.90 (GAAP diluted EPS of -$0.13). The company raised full-year adjusted EPS guidance to $12.52-$12.72, reaffirmed revenue guidance, executed a $2.0B accelerated share repurchase, and retired $2.1B of debt. BD named Vitor Roque (interim CFO since December 2025) as permanent EVP and CFO effective May 7, while Rick Byrd will retire after nearly 25 years (remaining through June 2026). On May 5, BD announced a strategic partnership with Wellstar Health System to integrate BD Pyxis Pro dispensing and BD Alaris infusion technologies with AI-powered medication inventory visibility. Barclays raised its PT to $204 from $202 with an Overweight rating post-earnings. Stock traded at $143.15 on May 11.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBDX jumps after Q2 results and raised FY2026 EPS outlookquiverquant.comBecton Dickinson price target raised to $204 from $202 at Barclaystipranks.com

BD reported Q2 FY2026 revenue of $4.714 billion (up 5.2% reported, 2.6% currency-neutral) with adjusted diluted EPS of $2.90 versus consensus of $2.78. The company raised its full-year adjusted EPS guidance to $12.52-$12.72 and reaffirmed revenue growth expectations. Effective May 7, 2026, BD named Vitor Roque executive vice president and CFO, after he served as interim CFO since December 2025. On May 5, BD announced a strategic partnership with Wellstar Health System to integrate BD Pyxis Pro dispensing and BD Alaris infusion technologies, powered by AI in BD Incada. BD also completed the divestiture of its Biosciences & Diagnostic Solutions business. Year-to-date the company has returned $2.3 billion to shareholders. The stock closed at $143.15 on May 11.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBD Appoints Vitor Roque Chief Financial Officerprnewswire.comBDX jumps after Q2 results and raised FY2026 EPS outlookquiverquant.com

BD reported Q2 FY2026 results on May 7: revenue of $4.71B (+5.2% reported / +2.6% FX-neutral) and adjusted EPS of $2.90 beating $2.78 consensus (4.5% beat). More than 90% of the portfolio delivered mid-single-digit growth; double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration. Adjusted operating margin 24.2%. BD raised FY26 adjusted EPS guidance to $12.52-$12.72 (from $12.35-$12.65). Vitor Roque named permanent EVP and CFO effective May 7 after internal/external search. Management confirmed Life Sciences separation has concluded. BD presented at Bank of America Healthcare Conference on May 12. Stock up 5.7% on results.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBDX jumps after Q2 results and raised FY2026 EPS outlookquiverquant.comBecton Dickinson (BDX) Q2 2026 Earnings Transcriptfool.com

Becton Dickinson reported fiscal Q2 2026 results May 7 with adjusted EPS of $2.90 beating $2.78 consensus by 4.32% and revenue of $4.7 billion exceeding $4.67B estimates. The company raised full-year adjusted EPS guidance to $12.52-$12.72 from $12.35-$12.65. Shares jumped ~6% in the biggest intraday rally since August. BD named Vitor Roque permanent CFO effective May 7. Revenue grew 2.6% FX-neutral with more than 90% of the portfolio delivering mid-single-digit growth and double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration. BD returned $2.3 billion to shareholders in H1 ($2B buybacks, $300M dividends). A partnership with Wellstar for AI-powered medication management was announced May 5. Risk: forex headwinds persist.

BD Q2 Fiscal 2026 Resultsinvestors.bd.comBDX Q2 FY26 Slidesinvesting.comBD Q2 2026 Earnings Transcriptfool.com

Becton Dickinson reported strong fiscal Q2 2026 results (ended March 31) with revenue of $4.71 billion exceeding $4.67 billion estimate, and adjusted EPS of $2.90 beating expectations. The company raised full-year 2026 adjusted EPS guidance range to $12.52-$12.72 from $12.35-$12.65. Appointed Vitor Roque, 25-year company veteran, as permanent Chief Financial Officer. Stock jumped 5.7% on earnings beat driven by strong drug-delivery and surgical equipment demand. Stifel Nicolaus cut price target to $175 from $215, but consensus remains Buy at $184.23 average target (27% upside).

Becton Dickinson Q2 2026 Earningsfool.comBecton Dickinson - Stock Price & News - CNBCcnbc.comBDX Stock Price & Overviewstockanalysis.com

Becton Dickinson delivered strong Q2 FY26 earnings with adjusted diluted EPS of $2.90 beating $2.78 estimate (+4.3%), revenue $4.7B slightly exceeding $4.67B forecast. US revenue grew 5.1% currency-neutral to $2.91B; international revenues slipped 1.4% to $1.8B. Generated $1.3B operating cash flow YTD and returned $2.3B to shareholders in H1 FY26 ($2B buybacks + $300M dividends). Appointed Vitor Roque as EVP/CFO effective May 7, made permanent after interim role since December 2025. Company raised FY26 EPS guidance to $12.52-$12.72 from $12.35-$12.65, at consensus estimate. Reaffirmed revenue guidance for low-single-digit growth. Stock up 5.7% today. Analyst consensus: Buy with average PT $184.23 (+27.3% upside).

Becton Dickinson Q2 FY26 earningsinvestors.bd.comBD EPS beat drives guidance raiseinvesting.comBecton Dickinson analyst ratingsfinance.yahoo.com